FTH Financials

Income Statement
MetricQ2 2026
Revenue
0
Cost of Revenue
0
Gross Profit
0
Operating Expenses
18.4M
R&D
9.2M
SG&A
9.2M
Operating Income
-18385000
EBITDA
-18360000
Net Income
-16007000
EPS (Basic)
$-2.84
EPS (Diluted)
$-2.84
Shares (Diluted)
5.6M
MarketsMoversWatchlist
Faeth Therapeutics (FTH) — Financials